With 44 offers, the company enterprise arm of Boehringer Ingelheim was probably the most lively company investor within the European life science market within the final 5 years.
The one different investor having reached the highest 5 rating in all three sectors (MedTech, HealthTech, and BioTech) was GV, with a complete of 29 offers.
In comparison with the Biotech sector, MedTech and HealthTech appear to be nonetheless pushed by non-public institutional traders as CVC investments seem like low.
Giant pharmaceutical corporations comparable to Boehringer Ingelheim, Merck, Novartis, and Johnson & Johnson proceed to play an vital function in VC financing within the BioTech sector.